The impact of the extent of lymph-node dissection on biochemical relapse after radical prostatectomy in node-negative patients

Anticancer Research

Volumn 30, Issue 6, 2010, Pages 2297-2302

  Schiavina, Riccardo ^a   Bertaccini, Alessandro ^a   Franceschelli, Alessandro ^a   Manferrari, Fabio ^a   Vagnoni, Valerio ^a   Borghesi, Marco ^a   Morselli Labate, Antonio M ^a   Martorana, Giuseppe ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Biochemical relapse; Lymph node metastasis; Micrometastasis; Pelvic lymph node dissection; Prostate cancer; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PARAMETER; PELVIC LYMPH NODE DISSECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ADULT; AGED; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 77955067863     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Briganti A, Blute ML, Eastham JH, Graefen M, Heidenreich A, Karnes JR, Montorsi F and Studer UE: Pelvic lymph node dissection in prostate cancer. Eur Urol 54: 1251-1265, 2009.
2. Heidenreich A, Varga Z and Von Knobloch R: Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 167: 1681-1686, 2002. (Pubitemid 34240702)
3. Joslyn SA and Konety BR: Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 68: 121-125, 2006. (Pubitemid 44037727)
4. Cagiannos I, Karakiewicz P, Eastham JA, Ohori M, Rabbani F, Gerigk C, Reuter V, Graefen M, Hammerer PG, Erbersdobler A,Huland H, Kupelian P, Klein E, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Strieker PD, Morash CG, Scardino PT and Kattan MW: A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 170: 1798-1803, 2003.
5. Briganti A, Chun FK, Salonia A, Zanni G, Scattoni V, Valiquette L, Rigatti P, Montorsi F and Karakiewicz PI: Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 49: 1019-1026, 2006.
6. Greene FL, Page DL, Fleming ID et al: AJCC Cancer Staging Manual, 6th ed. New York: Springer; 2002.
7. 11C-Choline positron emission tomography/computerized tomography for preoperative lymphnode staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 54: 392-401, 2008.
8. Bhatta-Dhar N, Reuther AM, Zippe C and Klein EA: No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer. Urology 63: 528-531, 2004.
9. Briganti A, Chun FK-H, Salonia A, Suardi N, Gallina A, Da Pozzo LF, Roscigno M, Zanni G, Valiquette L, Rigatti P, Montorsi F and Karakiewicz PI: Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol 50: 1006-1013, 2006.
10. Murphy AM, Berkman DS, Desai M, Benson MC, McKiernan JM and Badani KK: The number of negative pelvic lymph nodes removed does not affect the risk of biochemical failure after radical prostatectomy. BJU Int: 2009 Jun 22.
11. DiMarco DS, Zincke H, Sebo TJ, Slezak J, Bergstralh EJ and Blute ML: The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate-specific antigen era. J Urol 173: 1121-1125, 2005.
12. Masterson TA, Bianco Jr FJ, Vickers AJ, DiBlasio CJ, Fearn PA, Rabbani F, Eastham JA and Scardino PT: The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 175: 1320-1324, 2006.
13. Allaf ME, Palapattu GS, Trock BJ, Carter HB and Walsh PC: Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 172: 1840-1844, 2004.
14. Bader P, Burkhard FC, Markwalder R and Studer UE: Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 169: 849-854, 2003. (Pubitemid 36188105)
15. Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A and Studer UE: Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 54: 344-352, 2008.
16. Briganti A, Karnes JR, Da Pozzo LF, Cozzarini C, Gallina A, Suardi N, Bianchi M, Freschi M, Doglioni C, Fazio F, Rigatti P, Montorsi F and Blute ML: Two positive nodes represent a significant cut-off value for cancer-specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 55: 261-270, 2009.
17. Daneshmand S, Quek ML, Stein JP, Lieskovsky G, Cai J, Pinski J, Skinner EC and Skinner DG: Prognosis of patients with lymph node-positive prostate cancer following radical prostatectomy: long-term results. J Urol 172: 2252-2255, 2004.
18. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP and Zattoni F: EAU guidelines on prostate cancer. Eur Urol 53: 68-80, 2008.
19. Fujisawa M and Miyake H: Significance of micrometastases in prostate cancer. Surg Oncol 17: 247-252, 2008.
20. Pagliarulo V, Hawes D, Brands FH, Groshen S, Cai J, Stein JP, Lieskovsky G, Skinner DG and Cote RJ: Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol 24: 2735-2742, 2006.
21. Miyake H, Kurahashi T, Hara I, Takenaka A and Fujisawa M: Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy. BJU Int 99: 315-320, 2007.
22. Ferrari AC, Stone NN, Kurek R, Mulligan E, McGregor R, Stock R, Unger P, Tunn U, Kaisary A, Droller M, Hall S, Renneberg H,Livak KJ, Gallagher RE and Mandeli J: Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment. J Clin Oncol 24: 3081-3088, 2006.
23. Cheng L, Bergstralh EJ, Cheville JC, Slezak J, Corica FA, Zincke H, Blute ML and Bostwick DG: Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am J Surg Pathol 22: 1491-1500, 1998.
24. Fleischmann A, Schobinger S, Schumacher M, Thalmann GN and Studer UE: Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases. Prostate 69: 352-362, 2009.
25. Bittner N, Merrick GS, Wallner KE, Butler WM, Galbreath R and Adamovich E: Whole-pelvis radiotherapy in combination with interstitial brachytherapy: Does coverage of the pelvic lymph nodes improve treatment outcome in high-risk prostate cancer? Int J Radiat Oncol Biol Phys 2009.
26. Gofrit ON, Zorn KC, Steinberg GD, Zagaja GP and Shalhav AL: The Will Rogers phenomenon in urological oncology. J Urol 179: 28-33, 2008.